Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C38H51N3O12S2 |
Molecular Weight | 805.954 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC[C@]1(CC)CS(=O)(=O)C2=CC=C(C=C2[C@H]([C@H]1O)C3=CC(NC(=O)N[C@@H]4O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](OCC5=CC=CC=C5)[C@H]4O)=CC=C3)N(C)C
InChI
InChIKey=ULVBLFBUTQMAGZ-RTNCXNSASA-N
InChI=1S/C38H51N3O12S2/c1-5-7-18-38(6-2)23-54(46,47)30-17-16-27(41(3)4)20-28(30)31(35(38)44)25-14-11-15-26(19-25)39-37(45)40-36-33(43)34(51-21-24-12-9-8-10-13-24)32(42)29(53-36)22-52-55(48,49)50/h8-17,19-20,29,31-36,42-44H,5-7,18,21-23H2,1-4H3,(H2,39,40,45)(H,48,49,50)/t29-,31-,32-,33-,34+,35-,36-,38-/m1/s1
Volixibat (SHP626; formerly LUM002) is a potent inhibitor of the apical sodium-dependent bile acid transporter (ASBT) that was developed for the treatment of nonalcoholic steatohepatitis. Volixibat participated in phase II clinical trial to investigate its safety, effectiveness in adults with nonalcoholic steatohepatitis. However, this study was discontinued, without any further explanation for the possible causes. In addition, volixibat was studied in a clinical trial in healthy adults and in patients with type 2 diabetes mellitus, where was shown that the drug was generally well tolerated.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02787304
5 mg, 10 mg, and 20 mg of SHP626 (Volixibat) capsule by orally once daily in a double-blinded fashion
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C78276
Created by
admin on Sat Dec 16 09:46:50 GMT 2023 , Edited by admin on Sat Dec 16 09:46:50 GMT 2023
|
||
|
NCI_THESAURUS |
C2081
Created by
admin on Sat Dec 16 09:46:50 GMT 2023 , Edited by admin on Sat Dec 16 09:46:50 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Volixibat
Created by
admin on Sat Dec 16 09:46:50 GMT 2023 , Edited by admin on Sat Dec 16 09:46:50 GMT 2023
|
PRIMARY | |||
|
CD-118
Created by
admin on Sat Dec 16 09:46:50 GMT 2023 , Edited by admin on Sat Dec 16 09:46:50 GMT 2023
|
PRIMARY | |||
|
10072
Created by
admin on Sat Dec 16 09:46:50 GMT 2023 , Edited by admin on Sat Dec 16 09:46:50 GMT 2023
|
PRIMARY | |||
|
DB13914
Created by
admin on Sat Dec 16 09:46:50 GMT 2023 , Edited by admin on Sat Dec 16 09:46:50 GMT 2023
|
PRIMARY | |||
|
24987688
Created by
admin on Sat Dec 16 09:46:50 GMT 2023 , Edited by admin on Sat Dec 16 09:46:50 GMT 2023
|
PRIMARY | |||
|
1025216-57-2
Created by
admin on Sat Dec 16 09:46:50 GMT 2023 , Edited by admin on Sat Dec 16 09:46:50 GMT 2023
|
PRIMARY | |||
|
300000001420
Created by
admin on Sat Dec 16 09:46:50 GMT 2023 , Edited by admin on Sat Dec 16 09:46:50 GMT 2023
|
PRIMARY | |||
|
C152907
Created by
admin on Sat Dec 16 09:46:50 GMT 2023 , Edited by admin on Sat Dec 16 09:46:50 GMT 2023
|
PRIMARY | |||
|
DTXSID00109892
Created by
admin on Sat Dec 16 09:46:50 GMT 2023 , Edited by admin on Sat Dec 16 09:46:50 GMT 2023
|
PRIMARY | |||
|
X2JZ0451H8
Created by
admin on Sat Dec 16 09:46:50 GMT 2023 , Edited by admin on Sat Dec 16 09:46:50 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)